Table 2.

Study quality assessment of randomized controlled trials.

Author	Random allocation	Allocation concealment	Blinding	Any loss to follow-up	Analysis
Heinrich et al, 2014[8]	PY	NR	Patients: CN; caregivers: CN; data collectors: NR; adjudicators: NR; data analysis: NR.	CN	ITT: PY for efficacy outcomes Data for primary efficacy assessment available for 100% of randomized patients
Pillai et al, 2016[9]	DY	PY	Patients: CN; caregivers: CN; data collectors: NR; adjudicators: NR; data analysis: NR.	CN	ITT: DY for efficacy outcomes Data for primary efficacy assessment available for 100% of randomized patients
Mir et al, 2017[10]	DY	DY	Patients: CN; caregivers: CN; data collectors: NR; adjudicators: NR; data analysis: NR.	CN	ITT: DY for efficacy outcomes Data for primary efficacy assessment available for 100% of randomized patients
Rajan et al, 2018[11]	DY	DY	Patients: CN; caregivers: CN; data collectors: NR; adjudicators: NR; data analysis: NR.	CN	ITT: DY for efficacy outcomes Data for primary efficacy assessment available for 100% of randomized patients
Lodenius et al, 2018[12]	PY	CN	Patients: CN; caregivers: CN; data collectors: NR; adjudicators: NR; data analysis: NR.	CN	ITT: PN for efficacy outcomes Data for primary efficacy assessment available for 98.8% of randomized patients
Ng et al, 2018[13]	DY	DY	Patients: CN; caregivers: CN; data collectors: CN; adjudicators: NR; data analysis: NR.	CN	ITT: PN for efficacy outcomes Data for primary efficacy assessment available for 96.0% of randomized patients
Hanouz et al, 2019[14]	PY	PY	Patients: CN; caregivers: CN; data collectors: NR; adjudicators: NR; data analysis: NR.	CN	ITT: DY for efficacy outcomes Data for primary efficacy assessment available for 100% of randomized patients
Vourc’h et al, 2019[15]	DY	DY	Patients: CN; caregivers: CN; data collectors: NR; adjudicators: NR; data analysis: NR.	CN	ITT: DY for efficacy outcomes Data for primary efficacy assessment available for 100% of randomized patients
Wong et al, 2019[16]	DY	DY	Patients: CN; caregivers: CN; data collectors: NR; adjudicators: NR; data analysis: NR.	CN	ITT: DY for efficacy outcomes Data for primary efficacy assessment available for 100% of randomized patients
Tremey et al, 2020[17]	DY	PY	Patients: CN; caregivers: CN; data collectors: NR; adjudicators: NR; data analysis: NR.	CN	ITT: DY for efficacy outcomes Data for primary efficacy assessment available for 98.4% of randomized patients
Hua et al, 2020[18]	DY	PY	Patients: CN; caregivers: CN; data collectors: NR; adjudicators: NR; data analysis: NR.	CN	ITT: PN for efficacy outcomes Data for primary efficacy assessment available for 98.3% of randomized patients
Sjöblom et al, 2021[19]	DY	DY	Patients: CN; caregivers: CN; data collectors: NR; adjudicators: NR; data analysis: NR.	CN	ITT: PN for efficacy outcomes Data for primary efficacy assessment available for 99.7% of randomized patients
Osman et al, 2021[20]	DY	DY	Patients: CN; caregivers: CN; data collectors: NR; adjudicators: NR; data analysis: NR.	CN	ITT: PN for efficacy outcomes Data for primary efficacy assessment available for 94.3% of randomized patients
Lyons et al, 2021[21]	DY	DY	Patients: CN; caregivers: CN; data collectors: NR; adjudicators: NR; data analysis: NR.	CN	ITT: PN for efficacy outcomes Data for primary efficacy assessment available for 91.1% of randomized patients
Rosén et al, 2021[22]	DY	DY	Patients: CN; caregivers: CN; data collectors: NR; adjudicators: NR; data analysis: NR.	CN	ITT: PN for efficacy outcomes Data for primary efficacy assessment available for 90.0% of randomized patients
Zhou et al, 2021[23]	DY	DY	Patients: CN; caregivers: CN; data collectors: NR; adjudicators: NR; data analysis: NR.	CN	ITT: PN for efficacy outcomes Data for primary efficacy assessment available for 85.0% of randomized patients

CN = certainly no, DY = definitely yes, ITT = intention to treat, NR = not reported, PN = probably no, PY = probably yes.